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Abstract
Background: This study protocol adapts the traditional homeopathic drug proving methodology to a modern
clinical trial design.
Method: Multi-centre, randomised, double-blind, placebo-controlled phase 1 trial with 30 healthy volunteers. The
study consists of a seven day run-in period, a five day intervention period and a 16 day post-intervention
observation period. Subjects, investigators and the statisticians are blinded from the allocation to the study arm
and from the identity of the homeopathic drug. The intervention is a highly diluted homeopathic drug (potency
C12 = 10
24), Dose: 5 globules taken 5 times per day over a maximum period of 5 days. The placebo consists of an
optically identical carrier substance (sucrose globules). Subjects document the symptoms they experience in a
semi-structured online diary. The primary outcome parameter is the number of specific symptoms that characterise
the intervention compared to the placebo after a period of three weeks. Secondary outcome parameters are
qualitative differences in profiles of characteristic and proving symptoms and the total number of all proving
symptoms. The number of symptoms will be quantitatively analysed on an intention-to-treat basis using ANCOVA
with the subject’s expectation and baseline values as covariates. Content analysis according to Mayring is adapted
to suit the homeopathic qualitative analysis procedure.
Discussion: Homeopathic drug proving trials using the terminology of clinical trials according GCP and fulfilling
current requirements for research under the current drug regulations is feasible. However, within the current
regulations, homeopathic drug proving trials are classified as phase 1 trials, although their aim is not to explore the
safety and pharmacological dynamics of the drug, but rather to find clinical indications according to the theory of
homeopathy. To avoid bias, it is necessary that neither the subjects nor the investigators know the identity of the
drug. This requires a modification to the informed consent process and blinded study materials. Because it is
impossible to distinguish between adverse events and proving symptoms, both must be documented together.
Trial registration: ClinicalTrials.gov identifier: NCT01061229.
Background
Homoeopathic drug proving trials (HDP), also known as
homeopathic pathogenetic trials, is one of the funda-
mental concepts of homeopathy and has been con-
ducted for more than 200 years [1-4]. In addition to
exposing the toxic effects of the drug, HDP serve as a
key source of information for the homeopathic materia
medica. Its purpose is to test non-toxic levels of a speci-
fic substance in healthy volunteers to determine the
symptoms this substance stimulates and the types of
individuals who may be sensitive to it. The profile of
symptoms, recorded in an HDP by a group of healthy
volunteers, serve as basis for information to find indica-
tors of the drug in sick patients. In HDP, the drug
under investigation is administered and the individual
response of every volunteer to the application of the
substance is described. According to the law of similars,
the substance is then used to treat patients with similar
symptoms. The clinical experience subsequently shapes
the homeopathic drug profile.
A systematic review published in 2007 analysed HDP
conducted between 1945 and 1995, showed that most
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these old HDP studies were conducted by homeopathic
physicians who were mainly interested in identifying
clinical indications and drug profiles for therapeutic
purposes following the theory and philosophy of
homeopathy. However, in recent years innovative new
study methodology for HDP has been developed and
tested [5-10].
Recent research [11] has focussed on two main objec-
tives 1) using rigorous experimental designs to find out
if specific effects of highly diluted homeopathic drugs
compared to placebo or other controls can be identified
or reproduced and 2) qualitatively identifying new symp-
toms and indications mainly for therapeutic purposes.
Current research in HDP focuses on re-proving old
and commonly used homeopathic remedies in double-
blinded and placebo-controlled trials. In these studies
blinded homeopaths were asked to identify drug-speci-
fic symptoms in the diary of each study-subject and
assign them to a list of potential homeopathic drugs.
I nt h el a s tb l i n d e dH D Pc o n d u c t e db yt h i ss t u d y
group, two well-known homeopathic remedies
(Natrium muriaticum and Arsenicum album) were
tested against placebo. The blinded homeopaths identi-
fied only Arsenicum album-specific symptoms in the
Arsenicum album group, only Natrium muriatricum
specific symptoms in the Natrium muriaticum group
and only non-specific symptoms in the placebo group.
The results of this and a previous HDP showed that
specific symptoms of the HDP could be identified and
allocated by blinded raters with a high statistical signif-
icance [8,9,11]. To our knowledge, it is not clear
whether the identification of drug-specific symptoms
may also be achieved for new and unknown homeo-
pathic drugs. Therefore, in our opinion, a key question
of current HDP research is to define specific symp-
toms, including a list of criteria, and to develop a qua-
litative analysis method in order to identify them in
new and unknown homeopathic drugs.
Homeopaths and researchers have developed a variety
of study protocols for HDP and incorporated a variety
of modern standards in the last few years [2,3,12-16].
National and European authorities require that the
Guidelines for Good Clinical Practice (ICH GCP), the
Declaration of Helsinki and the national drug regula-
tions be applied for HDP and methodological and legal
consequences must be considered. The European Com-
mittee for Homoeopathy (ECH) developed the “Homo-
eopathic drug proving guideline” [2] which for the first
time, adapts traditional HDP methodology to the
requirements of modern European standards. German
drug regulations have meanwhile classified HDP as clini-
cal phase 1 trials. Within this study we developed,
for the first time, a study design methodology and a
study-protocol that fulfils the criteria of a phase-1-trial,
GCP, Declaration of Helsinki and German drug regula-
tions and also tests its applicability and feasibility in
practice. The main aim of the study is to determine
whether a homeopathic drug in the potency C12 pro-
vokes more characteristic homeopathic proving symp-
toms after three weeks compared to a placebo in
healthy volunteers. Therefore our hypotheses to test are:
H0: There is no difference between the number of
characteristic symptoms provoked by a homeopathic
drug in the potency C12 compared to placebo.
H1: There is a difference between the number of char-
acteristic symptoms provoked by a homeopathic drug in
the potency C12 compared to placebo.
Secondary aims are to develop and to test a qualitative
analysis methodology on which to base a definition for
drug-specific (characteristic) symptoms and to compile a
profile of characteristic homeopathic proving symptoms
of the drug being trialled for therapeutic purposes.
Methods
Study design
The homeopathic drug proving trial is to be conducted
as a multi-centre, randomised, double-blind, placebo-
controlled phase 1 trial. Subjects and investigators are
not only blinded to the group allocation process but
also to the identity of the drug.
Subjects
Volunteer medical students or medical doctors are
invited to take part in the trial by their investigators via
email or phone.
Subjects can be included if they fulfil the following
criteria: Medical doctors or medical students, over 18
years of age, who are not being treated for any acute or
chronic diseases on the day of inclusion, plus written
informed consent.
The following exclusion criteria apply: pregnant
women or nursing mothers are excluded as are anyone
who have received homeopathic treatment over the pre-
vious six weeks, or anyone who has participated in
another clinical trial during the last six months, anyone
with a personal or professional dependence on the study
physician or sponsor as well as anyone who has been
placed in hospital or other institution by authorities or
decree.
Investigators
The investigators are homeopathic medical doctors with
knowledge of HDP and who have at least three years
practical experience in homeopathic therapy. All investi-
gators are required to have completed a two-day certi-
fied and standardised investigator training programme
based on GCP, Declaration of Helsinki and the national
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procedures of this trial.
Ethics and consent
All subjects will provide written informed consent prior
to the inclusion in the trial. The trial will be performed
in accordance with International Conference on Harmo-
nisation Guidelines for Good Clinical Practice (ICH
GCP), Helsinki Declaration and national drug regula-
tions. Information about the trial will be provided dur-
ing one-on-one interviews with the help of a written
brochure for subjects. The study was approved by the
Berlin Ethics Committee (Landesamt für Gesundheit
und Soziales Berlin) on the 17th August 2009 (Refer-
ence: ZS EK 15, 287/09). The trial was registered under
ClinicalTrials.gov: Identifier NCT01061229.
Procedures
The study consists of a seven day run-in period (base-
line observation), a five day intervention period followed
by a 16 day follow-up period (see Figure 1).
Each study centre consists of one investigator who
supervises a maximum of three subjects. After giving
informed consent, subjects will receive an initial physical
examination, a full-length homeopathic interview of 60-
120 minutes duration and training on formal and technical
aspects of documentation prior to the run-in period,
which is carried out by their investigator. Until now In
HDP research there are no factors known to predict the
outcome. The following factors are assessed at baseline:
age, sex, education (medical student or doctor), history of
former chronic disease, former homeopathic treatment,
former participation in a homeopathic drug proving. Sub-
jects and investigators are also asked to rate their expecta-
tions about the subjects’ responsiveness to homeopathic
drugs as ordinals with 4 levels, as the authors presume
that this could be a factor related to the outcome.
Questions to subject
A. “How would you estimate your sensitivity to homeo-
pathic remedies in general?” - possible answers: strong
reaction/reaction/slight reaction/no reaction; B. “How
do you expect to react to the homeopathic drug?” -
answers: a very high number of symptoms/many symp-
toms/low number of symptoms/no symptoms.
Questions to investigators
A “How would you estimate your subject’s sensitivity to
homeopathic remedies in general?” - Response options:
same as above; B: “What is your expectation about your
subjects reaction to the homeopathic drug?” -r e s p o n s e
options same as above.
After starting the trial, subjects are required to docu-
ment daily any new or uncommon symptoms in a semi-
structured trial diary accessed through a secure internet
connection. It will provide a head-to-feet structure to be
filled in with free text. Every third day each subject will
be contacted by phone by his or her investigator. This
optimises the homeopathic quality of documentation,
which is considered crucial for a successful HDT [16]. A
very detailed description of symptoms experienced by
the subjects is essential for the quality of the homeo-
pathic drug proving trial. Of special importance are pre-
cise descriptions of locations, sensations, modalities,
concomitant symptoms, changes in mental or emotional
state. Any strange, individual, uncommon and peculiar
symptoms observed should be documented as these are
considered most important for the homeopathic pur-
pose. Investigators are only permitted to read and sepa-
rately comment on the documentation of their subjects.
The purpose of the supervision by the investigators and
the additional documentation is to highlight special
symptoms, improve documentation or mark special
observations as is common in HDP. Investigators are
not able to change the documentation of their subjects.
Their documentation is saved and stored separately.
Randomisation and treatment allocation
Based on the “ranuni” random number generator of the
SAS/STAT® software, subjects will be randomly allo-
cated to the interventions under study by block-rando-
misation stratified by centre (investigator). Both the
centres and subjects will be c o d e db ys i m p l en u m b e r s
unidentifiable by subjects, investigators and external per-
sons. The random list will be sent to the Charite’ central
pharmacy which will prepare sealed, sequentially num-
bered boxes containing the study medication and send
them to the centre. When a subject agrees to partici-
pate, the investigator opens the lowest numbered box
and gives him/her the study medication. Each centre
Figure 1 Organisation process in homeopathic drug proving.
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subject withdraws his/her consent or discontinues to the
study, he/she may not be included again. The planned
flow of participants through the homeopathic drug
proving trial is illustrated as flowchart in Figure 2.
Intervention
Subjects in the intervention group are instructed to take
five globules of the trial drug (potency C12), five times
per day for a maximum of five days (5×5×5). The study
medication is obtained from DHU (Germany), produced
according to the Hahnemannian method [17]. Subjects
are asked to stop taking the medication, in agreement
with their investigator, if they experience any of a prede-
fined set of proving symptoms (for definition see Table
1). Placebo consists of pure sucrose globules (DHU,
Germany) that are not potentiated nor impregnated
with alcohol. The administration scheme is identical in
the placebo control group to that of the intervention
group.
Outcome parameters
The primary outcome parameter is the number of charac-
teristic proving symptoms per subject, derived from the
qualitative data analysis of the homeopathic proving drug
compared to placebo within three weeks after the initial
dose of the drug or the placebo is administered. Defini-
tions of characteristic symptoms are given in Table 1.
Secondary outcome parameters are: the total number
of proving symptoms irrespective of whether they are
characteristic or not (definition of proving symptoms
see Table 1) and the number of serious adverse events.
Qualitative differences in the profiles of characteristic
proving symptoms from the homeopathic drug and the
placebo will also be compared and the inter-coder relia-
bility of the qualitative evaluation of characteristic prov-
ing symptoms will be calculated.
Sample size calculation
It is planned to include 30 healthy volunteers. Assuming
ad r o po u tr a t eo f2 0 % ,2 4s u b j e c t sw i l lb ea v a i l a b l ef o r
analysis. In this study, an unpaired t-test with a two-
sided level of 5% has a power of 80% to detect a group
difference of 20 ± 4 vs 15 ± 4 (mean ± standard devia-
tion) characteristic proving symptoms.
Analysis
The trial diaries with the data entries of subjects and
investigators provide the data for the qualitative and
quantitative analysis. The qualitative analysis will be car-
ried by experienced homeopathic doctors trained in
qualitative research methodology, the quantitative analy-
sis by a statistician.
Qualitative analysis
Data are coded by content analysis according to Mayring
[18] and analysed using Atlas.ti 5.2 software. Homeopathic
Figure 2 Flow of participants through the homeopathic drug
proving trial.
Table 1 Criteria for proving symptoms and characteristic symptoms
Criteria for proving symptoms Criteria for characteristic symptoms
New symptoms: the symptom is unfamiliar and has not been observed
within the last year or during the run-in-period
Characteristic symptoms are defined as proving symptoms with a
strongly individualistic character:
Study participant or study physician classify the symptom as new or
unusual
Symptoms affecting the whole organism of one or more study
participant
The study physician classifies the symptom as new in his final evaluation Symptoms affecting different organs or organ systems of one or more
study participant
A strong aggravation or modification of present (familiar) symptoms Symptoms accompanying a variety of other symptoms
Present familiar symptoms that have disappeared during the proving (cure) Symptoms that occur during the trial, which appear strange, peculiar or
unique to one or more study participants
Familiar symptoms from the past or present that have been cured or
strongly alleviated
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toms (Tables 1 and 2) serve as predefined categories for
the coding processes.
The qualitative data analysis consists of three steps:
categorisation of proving symptoms, categorisation of
characteristic symptoms, and context analysis (Figure 3).
After closing the trial, the investigators obtain the
complete body of text from the trial diary for each of
their subjects and are asked to categorise “proving
symptoms” in accordance to the prescribed definitions.
Subsequently, a second investigator reviews coding and
categorisation. In cases of contradictory categorisations,
a review committee of two investigators will decide on
the categorisation. At the end of this process, a list of
proving symptoms for each subject will be compiled.
The categorisation of characteristic symptoms is the
next step. To identify characteristic symptoms which
occurred in more than one subject, an inter-subject com-
parison of each study arm is needed. However, investiga-
tors will still be blinded from the treatment allocation.
This analysis is performed independently by two experi-
enced investigators. The inter-coder reliability is calculated
by the study statistician. The data is further structured into
the following categories: localities, sensations, modalities
and concomitants, times, mind and clinical findings.
Profiles of characteristic symptoms are compiled for
both groups which can now be compared qualitatively.
Context analysis is the final part and will be con-
ducted when the drug identity has been revealed at the
end of the trial. The results will be related to the tradi-
tional and scientific knowledge available on the drug
being investigated and discussed in the research team.
The aim is to find out whether the data fits into the
body of knowledge already available on the particular
drug and its plausibility.
Quantitative analysis
The main outcome will be analysed on an intention-to-
treat basis by univariate analyses of covariance
(ANCOVA) which includes the group (two levels), sub-
ject’s expectations (ordinal with 4 levels) and the respec-
tive baseline value (linear) as covariates. From these
model we will estimate the baseline adjusted treatment
effect and its 95% confidence interval (CI). The reported
P-value will be based on a two-sided t-test within this
model, and a P < 0.05 will be considered significant.
Missing values will be multiply imputed according to
Rubin’s suggestions [19]. In detail, 20 multiple copies of
the original data set will be generated, replacing missing
values by a randomly generated value according to the
MCMC algorithm. Each copy will be analysed as a com-
plete data set with the abovementioned ANCOVA
model and the results will be combined appropriately.
Sensitivity analyses will include some extensions of the
Table 2 Coding guideline for the homeopathic drug proving
Categories
+Subcategories
Definition Example Code (Example)
Locality Anatomic location where the symptom appears. Nose, chest. QL
+ specification + QL-nose
+ QL-chest
Sensation Sensation that is observed in a symptom. Stitch, dryness. QS
+ specification +QS-stitch
+QS-dryness
Modality Factors which aggravate (agg) or ameliorating (amel) a
symptom
Aggravation by cold wind,
amelioration
with warmth.
QM
+ specification +QM-agg-cold-wind
+QM-amel-warmth
Concomitant Symptoms that typically accompany other symptoms. Headaches accompany anticipatory
anxieties.
QC
+ specification +QC-headaches
Times Times when symptoms appear or disappear Headaches at 7 am. QT
+ specification +QT-7am
Mind Mental or emotional disturbances. Fear, sadness QM
+ specification +QM-fear
+QM-sadness
Clinical finding Clinical findings and signs. Eczema, sweating QF
+ specification +QM-eczema
+QM-sweating
Q = Quality; L = Locality; S = Sensation; M = Modality; C = Concomitant; T = Times; M = Mind; F = Clinical findings; agg = Aggravation; amel = Amelioration
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random factor and adding the center’s expectation (ordi-
nal with 4 levels) as an additional fixed factor.
Analyses of the secondary outcome parameters will
rely on the same statistical models, hereby replacing the
baseline value of the main outcome parameters by the
baseline value of the parameter under consideration.
All analyses will be performed using SAS/STAT®.
Discussion
This study transfers the traditional concept of homeo-
pathic drug proving trials into current clinical drug trial
methodology and standards and adapts it for the guide-
lines of the drug regulations for phase 1 trials. A stan-
dardised qualitative analysis procedure is combined with
quantitative analysis techniques. So far, our experience
suggests that designing homeopathic drug proving trials
using the terminology of clinical trials according GCP
and fulfilling the current requirements for research
under the national drug regulations is feasible. However,
there are some aspects differing from conventional stan-
dards that need to be discussed:
Classification as phase 1 trial
According to the German drug regulations, a homeo-
pathic drug proving trial is a phase 1 trial. The objec-
tive of a conventional phase 1 trial is to assess the
safety and to gain knowledge about their pharmacolo-
gical dynamics in a small number of subjects. In con-
trast, the aim of a homeopathic drug proving trial is to
identify new symptom patterns to identify therapeutic
indications according to the law of similars and
enhance the homeopathic knowledge and materia
medica [20]. The subjects are usually doctors or stu-
dents trained in homeopathy and not simply healthy
volunteers.
Informed consent and blinding
Another aspect is that in conventional trials it is neces-
sary to inform subjects and investigators about the iden-
tity of the drug, the risks and potential benefits. In an
HDP this has to be hidden from the subjects and inves-
tigators to avoid bias in detecting and reporting symp-
toms. After lengthy discussions regarding our study, the
Berlin ethics commission and the German health autho-
rities agreed on keeping the study blinded for the sub-
jects and investigators, but insisted on reporting the
identity of the trialled substance, its risks and potential
benefits to the authorities. This makes the whole proce-
dure more complicated, because most materials (e.g.
study protocol, investigators brochure) have to be pro-
duced in a blinded and a non-blinded version. We
decided that only two members of the study team (the
principal investigator and one study nurse) would know
the identity of the drug to minimize the risk of involun-
tarily disclosing the drug on trial.
Preclinical toxicological tests
In drug trials preclinical toxicological data are consid-
ered necessary before testing the substance in human
subjects. The risk of a substantial intoxication in
homeopathic drugs of a high potency is very low since
the compound is very dilute. The German drug agency
advises against preclinical toxicological tests in potencies
from C12 (10
-24) [21]. In our trial we will follow this
recommendation and use C12 potency.
Classification of Adverse Events
At present it is impossible to distinguish adverse events
from homeopathic proving symptoms due to a lack of
knowledge and subsequent criteria. In our homeopathic
drug proving trial, all symptoms are to be recorded in
an online diary by subjects and investigators. Severe
adverse events are to be separately documented and
reported to the sponsor, the ethical commission and the
health authorities, following the current regulations.
Figure 3 Data analysis process in homeopathic drug proving
trial.
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In the homeopathic community there is no consensus to
date on how to qualitatively analyse the trial data which
consists of large bodies of text. Criteria defining proving
symptoms exist, but it is unclear how to analyse them and
how reliable these criteria are. In this paper we suggest the
use of content analysis, according to Mayring [18], to ana-
lyse the texts, because it fulfils five basic criteria: 1. the
opportunity to categorise, 2. a combination of fixed and
open categorisation, 3. the applicability to the homeo-
pathic terminology, 4. the possibility to use software and 5.
the possibility to reproduce the analysis. However, this
method is used for homeopathic purposes and it is unclear
whether the chosen methodology will be fully suitable.
Indeed, this is a very crucial point: The qualitative analysis
is necessary following any quantitative analysis. If it fails,
all statistical results (including p-values), are potentially
biased. Therefore, we will test for reliability of the coding
of the primary outcome parameter characteristic proving
symptoms, which will be performed independently by two
experienced homeopaths. Therefore the results are also
dependent on the experience of the coding raters.
To optimally fulfil homeopathic criteria according to
Hahnemanns Organon (§143), we will use characteristic
proving symptoms as the primary outcome parameter.
We feel that this aligns with the homeopathic philoso-
phy of emphasizing the superior role of individualistic
and peculiar symptoms.
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